Loading
This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.
The registry lists NCT07553390 as not yet recruiting, last updated 2026-08-19. Enrolment is 60 planned participants, an estimate. Interventions: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/